參考文獻 |
Dykstra, R.L. and Robertson, T. (1982) An algorithm for isotonic regression for two or more independent variables. The Annals of Statistics; 10:708-716.
Guo, B., Garrett-Mayer, E. and Liu, S. (2021) A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent. Journal of the Royal Statistical Society: Series C Applied Statistics; 70:1210-1229.
Liu, S. and Yuan, Y. (2015) Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society: Series C Applied Statistics; 64:507-523.
Lin, R. and Yin, G. (2017) Bayesian optimal interval design for dose finding in drug-combination trials. Statistical Methods in Medical Research; 26:2155-2167.
Lin, R., Zhou, Y., Yan, F., Li, D., Yuan, Y. (2020) BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precision Oncology; 4:1393-1402.
O′Quigley, J., Pepe, M., Fisher, L. (1990) Continual Reassessment Method: A practical design for phase I clinical trials in cancer. Biometrics; 46:33-48.
Pan, H., Lin, R., Zhou, Y., Yuan, Y. (2020) Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials; 92:105972.
Riviere, M. K., Yuan, Y., Dubois, F., and Zohar, S. (2014) A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharmaceutical Statistics; 13: 247–257.
Riviere, M.K., Yuan, Y., Dubois, F., Zohar, S. (2015) A Bayesian dose-finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent. Journal of the Royal Statistical Society: Series C Applied Statistics; 64:215-229.
Shimamura, F., Hamada, C., Matsui, S., and Hirakawa, A. (2018) Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials. Journal of Biopharmaceutical Statistics; 28:1025-1037.
Wages, N. A., Conaway, M. R. (2014) Phase I/II adaptive design for drug combination oncology trials. Statistics in Medicine; 33:1990-2003.
Wheeler, G. M., Sweeting, M. J., and Mander, A. P. (2019) A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data. Journal of the Royal Statistical Society: Series C Applied Statistics; 68:309-329.
Yuan, Y. and Yin, G. (2011) Bayesian phase I/II adaptively randomized oncology trials with combined drugs. The Annals of Applied Statistics; 5:924-942.
Zhou, Y., Lee, J.J., Yuan, Y. (2019) A Utility-based Bayesian Optimal Interval (U-BOIN) Phase I/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies. Statistics in Medicine; 38:5299-5316.
黃致杰,「複合藥之早期臨床試驗設計」,國立中央大學,碩士論文,民國111年。 |